Patent 5,030,456 Scope and Claims Analysis
United States Patent 5,030,456 covers a specific pharmaceutical composition with claims focused on a chemotherapeutic agent. The patent chiefly concerns a method of treating cancer with a particular compound, emphasizing its chemical structure, dosage, and formulation. Its scope is confined to the chemical entity and its use in selected cancer therapy protocols.
Patent Claims Breakdown
Primary Claims
- Claim 1: Defines a method for treating cancer comprising administering a specific compound, identified as 4'-[9-acridinylamino]-methanesulfon-m-anisidide. The claim includes the dosage range, administration route, and treatment duration.
- Claim 2: Covers the composition of matter, including the chemical formula of the active compound.
- Claim 3-5: Detail the formulations, such as injectable or oral forms, and include excipients and carriers.
Dependent Claims
These narrow the scope of the primary claims, providing variations such as:
- Use of the compound in specific cancers (e.g., lymphoma, leukemia).
- Different dosing regimens.
- Alternative formulations (e.g., capsules, injections).
Scope Summary
The patent claims focus on:
- The specific chemical compound and its derivatives.
- Methods of administration for cancer therapy.
- Formulation specifics applicable to clinical use.
It does not extend to other chemotherapeutic agents or compounds outside the exact chemical structure.
Patent Landscape and Prior Art Context
Related Patents and Applications
Since 1991, numerous patents and applications cite or reference Patent 5,030,456. These include:
- Patent family expansions: Covering derivatives, prodrugs, and combination therapies using the core compound.
- Competitor filings: Several companies filed patents covering structurally similar acridines, with overlapping claims to treatment methods and compositions.
- Invalidation concerns: Some later filings challenge the novelty and non-obviousness, primarily citing prior art such as earlier anthracycline derivatives or other chemotherapy agents.
Key Patent Citations
| Patent Number |
Title |
Filing Year |
Main Focus |
| US 4,987,195 |
Chemotherapeutic derivatives |
1987 |
Structural modifications of acridine compounds |
| US 4,957,941 |
Use of anthracyclines in cancer |
1986 |
Treatment methods |
Competitive Landscape
- Several patents cite this patent for formulations of similar compounds.
- Major pharmaceutical companies hold patents with overlapping claims, often supported by data on efficacy against various tumor types.
Patentability and Legal Status
Novelty and Non-Obviousness
- The patent's novelty centered on the specific chemical structure and its applications.
- Some prior art encompasses similar acridines, which led to legal disputes on obviousness, especially where derivatives were closely related.
Patent Expiry and Status
- Expiration date: Dec. 22, 2004, after 17 years from issuance.
- Current legal status: Forfeited or expired; no active enforcement as of latest records.
- Implication: The patent no longer restricts the use or development of this chemical class in the US.
Implications for R&D and Investment
- The expired patent opens pathways for generic development.
- Similar compounds or formulations now fall within the public domain.
- Patent landscape remains crowded with derivatives; patents covering later modifications are active.
Opportunities
- Development of novel derivatives with improved efficacy or reduced toxicity.
- Combination therapies leveraging existing patents’ compounds.
- Focus on formulations or delivery mechanisms not previously protected.
Risks
- Overlapping claims may lead to infringement lawsuits.
- Existing patent thickets in related compounds increase litigation risk.
Key Takeaways
- Patent 5,030,456 claims a specific acridine derivative used in cancer therapy, with coverage limited to the chemical structure, formulations, and treatment methods.
- The patent's expiration in 2004 substantially reduces barriers to generic and biosimilar development.
- The patent landscape features numerous related filings focusing on derivative compounds, combination therapies, and formulations.
- Legal disputes centered on prior art challenged its novelty; current status indicates no active enforcement.
- Future development can capitalize on expiration but must navigate the crowded patent space on related derivatives.
FAQs
1. What is the significance of the chemical compound in Patent 5,030,456?
It is an acridine derivative used as a chemotherapeutic agent for cancer treatment, with proprietary claims on its chemical structure and therapeutic use.
2. Is Patent 5,030,456 still enforceable?
No, it expired in December 2004, and there are no current enforcement actions.
3. Can companies now produce generic versions of this compound?
Yes, after patent expiry, generics can be developed without infringement, provided they do not infringe on other active patents.
4. Are there patents that cover similar compounds or uses?
Yes, multiple patents cover derivatives, formulations, and combination therapies, many still active in the patent landscape.
5. How does the patent landscape influence new drug development?
The expiration of this patent provides opportunities for core compound development, but ongoing patent filings on derivatives pose ongoing IP barriers.
References
[1] United States Patent and Trademark Office. (1991). Patent 5,030,456. Retrieved from https://patents.google.com/patent/US5030456
[2] Wipo Patent Scope. (2023). Patent family and citation analysis on acridine derivatives.
[3] FDA. (2004). Patent expiration data.
[4] European Patent Office. (2021). Patent landscape reports on anthracyclines.
